Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 1, 2013, Pages 153-163

  Litviakov, Nicolay V ^a   Cherdyntseva, Nadezhda V ^a,b   Tsyganov, Matvey M ^a   Denisov, Evgeny V ^a   Garbukov, Evgeny Y ^a   Merzliakova, Marina K ^a   Volkomorov, Victor V ^a   Vtorushin, Sergey V ^a,b   Zavyalova, Marina V ^a,b   Slonimskaya, Elena M ^a,b   Perelmuter, Vladimir M ^a,b  

^a CANCER RESEARCH INSTITUTE   (Russian Federation)

^b SIBERIAN STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Breast cancer; Chemotherapy; Gene expression; Multidrug resistance

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN;

ABCB1 GENE; ABCC1 GENE; ABCC2 GENE; ABCC3 GENE; ABCC5 GENE; ABCG2 GENE; ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; EXPRESSION VECTOR; FEMALE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GSTP1 GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE GENE; MULTIPLE CYCLE TREATMENT; MVP GENE; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; HUMANS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; UP-REGULATION;

EID: 84872313096     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1992-x     Document Type: Article

References (54)

1. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5(3):219-234. doi: 10.1038/nrd1984
2. Leonessa F, Clarke R (2003) ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10(1):43-73
3. Fletcher JI, Haber M, Henderson MJ, Norris MD (2010) ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 10(2):147-156. doi: 10.1038/nrc2789
4. Kuo MT (2007) Roles of multidrug resistance genes in breast cancer chemoresistance. Adv Exp Med Biol 608:23-30
5. Wind N, Holen I (2011) Multidrug resistance in breast cancer-from in vitro models to clinical studies. Int J Breast Cancer 2011:1-12. doi: 10.4061/2011/967419
6. Gillet JP, Efferth T, Remacle J (2007) Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 1775(2):237-262. doi: 10.1016/j.bbcan.2007.05.002
7. Gillet JP, Gottesman MM (2011) Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. Curr Pharm Biotechnol 12(4):686-692
8. Vasieva O (2011) The many faces of glutathione transferase pi. Curr Mol Med 11(2):129-139
9. Mossink MH, van Zon A, Scheper RJ, Sonneveld P, Wiemer EA (2003) Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene 22(47):7458-7467. doi: 10.1038/sj.onc.1206947
10. Schwartz GF, Hortobagyi GN (2004) Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer 100(12):2512-2532. doi: 10.1002/cncr.20298
11. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD (1977) Assessment of response to therapy in advanced breast cancer: a project of the programme on clinical oncology of the International union against cancer, Geneva. Switz Cancer 39(3):1289-1294
12. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9):e45
13. Steinbach D, Lengemann J, Voigt A, Hermann J, Zintl F, Sauerbrey A (2003) Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia. Clin Cancer Res 9(3):1083-1086
14. Nishimura M, Yoshitsugu H, Naito S, Hiraoka I (2002) Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 122(5):339-361
15. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP (2008) Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26(5):814-819. doi: 10.1200/JCO.2007.15.3510
16. Caudle AS, Gonzalez-Angulo AM, Hunt KK, Liu P, Pusztai L, Symmans WF, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F (2010) Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(11):1821-1828. doi: 10.1200/JCO.2009.25.3286
17. Precht LM, Lowe KA, Atwood M, Beatty JD (2010) Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival. Breast J 16(4):362-368. doi: 10.1111/j.1524-4741.2010. 00935.x
18. Alba E, Calvo L, Albanell J, De la Haba JR, Arcusa Lanza A, Chacon JI, Sanchez-Rovira P, Plazaola A, Lopez Garcia-Asenjo JA, Bermejo B, Carrasco E, Lluch A (2012) Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol. doi: 10.1093/annonc/mds132
19. Berruti A, Brizzi MP, Generali D, Ardine M, Dogliotti L, Bruzzi P, Bottini A (2008) Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions. Oncologist 13(11):1137-1148. doi: 10.1634/ theoncologist.2008-0162
20. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P, Untch M, Blohmer JU, Sinn HP, Sittek R, Souchon R, Tulusan AH, Volm T, Senn HJ (2003) International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21(13):2600-2608. doi: 10.1200/JCO.2003.01.136
21. Fumagalli D, Desmedt C, Ignatiadis M, Loi S, Piccart M (2011) Sotiriou C (2011) Gene profiling assay and application: the predictive role in primary therapy. J Natl Cancer Inst Monogr 43:124-127. doi: 10.1093/jncimonographs/ lgr040
22. Nagasaki K, Miki Y (2008) Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer. Breast Cancer 15(2):117-120. doi: 10.1007/s12282-008-0031-6
23. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Caldas C, Aparicio S, Brenton JD, Ellis I, Huntsman D, Pinder S, Purushotham A, Murphy L, Bardwell H, Ding Z, Jones L, Liu B, Papatheodorou I, Sammut SJ, Wishart G, Chia S, Gelmon K, Speers C, Watson P, Blamey R, Green A, Macmillan D, Rakha E, Gillett C, Grigoriadis A, di Rinaldis E, Tutt A, Parisien M, Troup S, Chan D, Fielding C, Maia AT, McGuire S, Osborne M, Sayalero SM, Spiteri I, Hadfield J, Bell L, Chow K, Gale N, Kovalik M, Ng Y, Prentice L, Tavare S, Markowetz F, Langerod A, Provenzano E, Borresen-Dale AL (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346-352. doi: 10.1038/nature10983
24. Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, Gonzalez-Angulo AM, Mills GB, Pinto JA, Gomez HL, Arteaga CL (2012) Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med 18:1052-1059. doi: 10.1038/nm.2795
25. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacon JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF (2011) A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305(18):1873-1881. doi: 10.1001/jama.2011.593
26. Keskin S, Muslumanoglu M, Saip P, Karanlik H, Guveli M, Pehlivan E, Aydogan F, Eralp Y, Aydiner A, Yavuz E, Ozmen V, Igci A, Topuz E (2011) Clinical and pathological features of breast cancer associated with the pathological complete response to anthracycline-based neoadjuvant chemotherapy. Oncology 81(1):30-38. doi: 10.1159/000330766
27. Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L (2012) Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 19(5):1508-1516. doi: 10.1245/s10434-011-2108-2
28. Lacave R, Coulet F, Ricci S, Touboul E, Flahault A, Rateau JG, Cesari D, Lefranc JP, Bernaudin JF (1998) Comparative evaluation by semiquantitative reverse transcriptase polymerase chain reaction of MDR1, MRP and GSTp gene expression in breast carcinomas. Br J Cancer 77(5):694-702
29. Moureau-Zabotto L, Ricci S, Lefranc JP, Coulet F, Genestie C, Antoine M, Uzan S, Lotz JP, Touboul E, Lacave R (2006) Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. Br J Cancer 94(4):473-480. doi: 10.1038/sj.bjc.6602958
30. Linn SC, Pinedo HM, van Ark-Otte J, van der Valk P, Hoekman K, Honkoop AH, Vermorken JB, Giaccone G (1997) Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 71(5):787-795
31. Chevillard S, Pouillart P, Beldjord C, Asselain B, Beuzeboc P, Magdelenat H, Vielh P (1996) Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77(2):292-300. doi: 10.1002/(SICI)1097- 0142(19960115)77:2<292:AID-CNCR11>3.0.CO;2-X
32. Atalay C, Deliloglu Gurhan I, Irkkan C, Gunduz U (2006) Multidrug resistance in locally advanced breast cancer. Tumour Biol 27(6):309-318. doi: 10.1159/000096086
33. Faneyte IF, Kristel PM, van de Vijver MJ (2004) Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. Anticancer Res 24(5A):2931-2939
34. Faneyte IF, Kristel PM, van de Vijver MJ (2001) Determining MDR1/P-glycoprotein expression in breast cancer. Int J Cancer 93(1):114-122. doi: 10.1002/1097-0215(20010701)93:1<114:AID-IJC1309>3.0.CO;2-J
35. Singh LC, Chakraborty A, Mishra AK, Devi TR, Sugandhi N, Chintamani C, Bhatnagar D, Kapur S, Saxena S (2012) Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women. Med Oncol 29(2):539-546. doi: 10.1007/s12032-011-9952-6
36. Gillet JP, Efferth T, Steinbach D, Hamels J, de Longueville F, Bertholet V, Remacle J (2004) Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res 64(24):8987-8993. doi: 10.1158/0008-5472.CAN-04-1978
37. Glubb DM, Innocenti F (2011) Mechanisms of genetic regulation in gene expression: examples from drug metabolizing enzymes and transporters. WIREs Syst Biol Med 3:299-313. doi: 10.1002/wsbm.125
38. Sharma G, Mirza S, Parshad R, Srivastava A, Datta Gupta S, Pandya P, Ralhan R (2010) CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clin Biochem 43(4-5):373-379. doi: 10.1016/j.clinbiochem.2009.10.009
39. Reed K, Parissenti AM (2010) Epigenetic regulation of ABCB1 transporter expression and function. Curr Pharmacol 8(3):218-231
40. Johnson RA, Ince TA, Scotto KW (2001) Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem 276(29):27716-27720. doi: 10.1074/jbc.C100121200
41. Thottassery JV, Zambetti GP, Arimori K, Schuetz EG, Schuetz JD (1997) p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 94(20):11037-11042
42. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, Wang Q, Zambetti GP, Schuetz JD (2001) Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 276(42):39359-39367. doi: 10.1074/jbc.M103429200
43. Hanafy S, Salem T, El-Aziz A, EL-Fiky B, Shokair M (2011) Influence of anticancer drugs on DNA methylation in liver of female mice. Am J Mol Biol 1:62-69. doi: 0.4236/ajmb.2011.12008
44. Samlowski WE, Leachman SA, Wade M, Cassidy P, Porter-Gill P, Busby L, Wheeler R, Boucher K, Fitzpatrick F, Jones DA, Karpf AR (2005) Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol 23(17):3897-3905. doi: 10.1200/JCO.2005.06.118
45. Wilting RH, Dannenberg JH (2012) Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist Updat 15:21-38. doi: 10.1016/j.drup.2012.01.008
46. Sui H, Fan ZZ, Li Q (2012) Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res 40(2):426-435
47. Weinstein-Oppenheimer CR, Henriquez-Roldan CF, Davis JM, Navolanic PM, Saleh OA, Steelman LS, Franklin RA, Robinson PJ, McMahon M, McCubrey JA (2001) Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin Cancer Res 7(9):2898-2907
48. Iorio MV, Croce CM (2012) microRNA involvement in human cancer. Carcinogenesis. doi: 10.1093/carcin/bgs140
49. Hu H, Gatti RA (2011) MicroRNAs: new players in the DNA damage response. J Mol Cell Biol 3(3):151-158. doi: 10.1093/jmcb/mjq042
50. Litviakov NV, Cherdyntseva NV, Tsyganov MM, Denisov EV, Merzliakova MK, Garbukov EY, Vtorushin SV, Zavyalova MV, Slonimskaya EM (2011) Influence of gene polymorphism on the expression of the multidrug resistance genes in breast tumor during neoadjuvant chemotherapy. Med Genet (Russ) 10(10):37-43
51. Gervas PA, Litviakov NV, Stakcheeva MN, Miller SV, Dobrodeev AY, Garbukov EY, Babyshkina NN, Kukharev YV, Vasilieva MV, Slonimskaya EM, Belyavskaya VA, Tuzikov SA, Cherdyntseva NV (2009) Influence of apoptosis and repair gene polymorphism on neoadjuvant chemotherapy response of malignant tumors. Sib J Oncol (Russ) 4(34):41-47
52. Zavyalova MV, Perelmuter VM, Vtorushin SV, Denisov EV, Litvyakov NV, Slonimskaya EM, Cherdyntseva NV (2011) The presence of alveolar structures in invasive ductal NOS breast carcinoma is associated with lymph node metastasis. Diagn Cytopathol. doi: 10.1002/dc.21852
53. Denisov E, Tsyganov M, Tashireva L, Zavyalova M, Perelmuter V, Cherdyntseva N (2012) Intratumoral heterogeneity in expression of chemotherapy response markers in invasive ductal breast carcinoma NOS. 4th WIN Symposium: efficacy of biomarkers and personalized cancer therapeutics, Paris, France. Ann Oncol 23(5):v21-v22
54. Zavyalova MV, Litvyakov NV, Garbukov EY, Vtorushin SV, Stakheeva MN, Savenkova OV, Kritskaya NG, Perelmuter VM, Slonimskaya EM, Cherdyntseva NV (2008) Relationship between tumor sensitivity to neoadjuvant chemotherapy and histologic pattern of primary tumor in unicentric infiltrating ductal breast carcinoma. Sib J Oncol (Russ) 6:30-34